Swiss National Bank
ORIC icon

Swiss National Bank’s Oric Pharmaceuticals ORIC Stock Holding History

Swiss National Bank’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Hold
86,200
– – ﹤0.01% 2121
2025
Q4 		$705K Buy
86,200
+20,100
+30% +$231K ﹤0.01% 2251
2025
Q3 		$793K Buy
+66,100
New +$695K ﹤0.01% 2236
2025
Q2 		– Sell
-68,400
Closed -$382K – 2384
2025
Q1 		$382K Buy
68,400
+6,000
+10% +$52.5K ﹤0.01% 2375
2024
Q4 		$504K Buy
62,400
+3,200
+5% +$29.4K ﹤0.01% 2405
2024
Q3 		$607K Sell
59,200
-7,100
-11% -$70.2K ﹤0.01% 2389
2024
Q2 		$469K Buy
+66,300
New +$593K ﹤0.01% 2426
2022
Q2 		– Sell
-60,600
Closed -$324K – 2776
2022
Q1 		$324K Buy
60,600
+4,300
+8% +$38.7K ﹤0.01% 2656
2021
Q4 		$828K Buy
56,300
+3,700
+7% +$57.7K ﹤0.01% 2543
2021
Q3 		$1.1M Hold
52,600
– – ﹤0.01% 2392
2021
Q2 		$930K Sell
52,600
-9,700
-16% -$213K ﹤0.01% 2509
2021
Q1 		$1.53M Buy
62,300
+21,700
+53% +$686K ﹤0.01% 2158
2020
Q4 		$1.37M Buy
+40,600
New +$1.16M ﹤0.01% 2135

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Swiss National Bank's ORIC Position: Q1 2026 in Review

Swiss National Bank held its Oric Pharmaceuticals (ORIC) position steady in Q1 2026 at 86,200 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

Swiss National Bank first reported a position in ORIC in Q4 2020 and has held it in 13 quarters since. The position peaked at $1.53M in Q1 2021. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Swiss National Bank held 86,200 shares of Oric Pharmaceuticals worth $1.09M as of Q1 2026.
  • Swiss National Bank left its Oric Pharmaceuticals share count unchanged in Q1 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #2121 holding.
  • Swiss National Bank first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
  • Swiss National Bank's Oric Pharmaceuticals position peaked at $1.53M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.